SignIn
Kerala Kaumudi Online
Tuesday, 22 June 2021 12.23 AM IST

Bleeding, clotting events following COVID vaccination 'minuscule' in India: Govt report

vaccine-complications-

​​​​​​NEW DELHI: Bleeding and clotting cases following COVID vaccination in India are "minuscule" and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI (Adverse Event Following Immunization) Committee to the Ministry of Health & Family Welfare said on Monday.


The report comes in the backdrop of alerts being raised in some countries on post-vaccination “embolic and thrombotic events" on 11 March 2021 particularly with the AstraZeneca-Oxford vaccine, which is the Covishield vaccine candidate administered in India and manufactured by Serum Institute.


"A decision was taken to conduct an urgent in-depth analysis of the adverse events (AE) in India in the light of the global concerns." the government said in a statement.


As per the report, the National AEFI committee noted that as of 03 April 2021, 75,435,381 vaccine doses had been administered (Covishield – 68,650,819; Covaxin – 6,784,562). Of these, 65,944,106 were first doses and 9,491,275 second dose. Since the COVID-19 vaccination drive was initiated – more than 23,000 adverse events were reported through the CO-WIN platform reported from 684 of the 753 districts of the country. Of these, only 700 cases (@ 9.3 cases /million doses administered) were reported to be serious and severe nature.


The AEFI Committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases have been reported to be potential thromboembolic (formation of a clot in a blood vessel that might also break loose and carried by the bloodstream to plug another vessel) events – following the administration of Covishield vaccine – with a reporting rate of 0.61 cases/ million doses, the statement added.


There were no potential thromboembolic events reported following administration of the Covaxin vaccine.

AEFI data in India showed that there is a very minuscule but definitive risk of thromboembolic events. The reporting rate of these events in India is around 0.61/million doses, which is much lower than the 4 cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses.


"It is important to know that thromboembolic events keep occurring in the general population as background and scientific literature suggests that this risk is almost 70 per cent less in persons of South and South-East Asian descent in comparison to those from European descent," the report stated.


Moreover, the Union health ministry is separately issuing advisories to Healthcare Workers and Vaccine Beneficiaries to encourage people to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any COVID-19 vaccine (particularly Covishield) and report preferably to the health facility where vaccine was administered.

The symptoms are:


-breathlessness;

-pain in chest;

-pain in limbs/pain on pressing limbs or swelling in limbs (arm or calf);

-multiple, pinhead size red spots or bruising of skin in an area beyond the injection site;

-persistent abdominal pain with or without vomiting;

-seizures in the absence of previous history of seizures with or without vomiting;

-severe and persistent headache with or without vomiting (in the absence of previous history of migraine or chronic headache);

-weakness/paralysis of limbs or any particular side or part of the body (including face);

-persistent vomiting without any obvious reason;

-blurred vision or pain in eyes or having double vision;

-change in mental status or having confusion or depressed level of consciousness

-Any other symptom or health condition which is of concern to the recipient of the family

The government also added that Covishield, the COVID-19 vaccine, continues to have a definite positive benefit-risk profile with tremendous potential to prevent infections and reduce deaths due to COVID-19 across the world and in India.


"MoHFW is continuously monitoring the safety of all COVID-19 vaccines and is promoting reporting of suspected adverse events," it said.


Meanwhile, the government added that more than two crore COVID-19 vaccine doses are still available with the states and Union territories, while nearly three lakh doses are in the pipeline and will be received by them within the next three days, the Union health ministry said on Monday.


The Centre has so far provided over 20 crore (20,76,10,230) vaccine doses to the states and Union territories for free. Of this, the total consumption, calculated on the basis of average figures, up to May 16, including wastage, is 18,71,13,705 doses (according to data available at 8 am on Monday), it added.


Furthermore, 2,94,660 vaccine doses are in the pipeline and will be received by the states within the next three days, it said.

JOIN THE DISCUSSION
TAGS: VACCINATION, BLEEDING, CLOTTING, COVID VACCINATION, GOVT REPORT, AEFI, ASTRAZENECA-OXFORD, COVIDSHIELD
KERALA KAUMUDI EPAPER
TRENDING IN INDIA
TRENDING IN INDIA
X
Lorem ipsum dolor sit amet
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
We respect your privacy. Your information is safe and will never be shared.